In Phase C, individuals will get ABBV-744 and oral navitoclax. In Section D, individuals will obtain ABBV-744 and ruxolitinib. Individuals will obtain treatment until eventually condition progression or the contributors are unable to tolerate the study drugs. Celastrol was discovered being a Myb inhibitor that suppressed C/EBPβ activity and repressed https://abbv-744-in-acute-myeloid24578.angelinsblog.com/31285974/details-fiction-and-clinical-effectiveness-of-abbv-744-in-aml-patients